AbCellera Biologics (ABCL) Return on Sales (2020 - 2026)

AbCellera Biologics' Return on Sales history runs 7 years deep, the most recent figure standing at 0.05% for Q1 2026.

• Quarterly Return on Sales rose 6.0% year-over-year to 0.05% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.02% (up 5.0% YoY) and the FY2025 annual result came in at 0.02%, up 4.0% from the prior year.
• Return on Sales was 0.05% for Q1 2026 at AbCellera Biologics, down from 0.0% in the prior quarter.
• Across five years, Return on Sales topped out at 0.01% in Q1 2022 and bottomed at 0.11% in Q1 2025.
• A 5-year average of 0.04% and a median of 0.04% in 2024 frame the typical range for Return on Sales.
• Peak annual rise in Return on Sales reached 7 bps in 2025, while the deepest fall reached 7 bps in 2025.
• AbCellera Biologics' Return on Sales stood at 0.01% in 2022, then slumped by 270 bps to 0.05% in 2023, then slumped by 32 bps to 0.07% in 2024, then jumped by 97 bps to 0.0% in 2025, then sank by 2503 bps to 0.05% in 2026.
• Business Quant data shows ABCL's Return on Sales at 0.05% in Q1 2026, 0.0% in Q4 2025, and 0.06% in Q3 2025.